Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults - Test2 - elhamkhani - TriplyDB

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults

http://www.wikidata.org/entity/Q34154300

about

Recent progress in West Nile virus diagnosis and vaccination The yellow fever 17D virus as a platform for new live attenuated vaccines West Nile Virus: biology, transmission, and human infection A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations Plant-made vaccines against West Nile virus are potent, safe, and economically feasible Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Current trends in West Nile virus vaccine development.The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys Comparison of β-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody A review of vaccine approaches for West Nile virus.TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate West Nile virus state of the art report of MALWEST Project.Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.West Nile virus infection and immunity.Technologies for the development of West Nile virus vaccines.Current status and future prospects of yellow fever vaccines.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects.Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.West nile virus.The Immune Responses of the Animal Hosts of West Nile Virus: A Comparison of Insects, Birds, and Mammals.

P2860

Q21284433-5C92053B-7E94-4376-B56A-E15DE0B619CF Q26865102-954FC575-2847-4184-87B2-26FE3F9EA141 Q26865618-617E8157-59B3-47F2-9CCF-B4E951D9B2AB Q27321020-4B150EBA-3FDA-4E72-A7E9-B7BB68F41BE8 Q28082778-30846B25-D50C-42E6-980C-C20DAAD26C47 Q30250251-D3A8715B-3DA2-4AEB-BC1C-AFE7D52982C1 Q33584872-19DD09DE-6461-4594-9649-4D318213CBF1 Q33909344-96FAC240-C11A-4D58-BDFC-373D2E6BE341 Q34788758-2174677D-58E0-45A4-A2CA-C7DD2617C7BB Q35492767-EF889C18-71B0-41D1-AE49-3FBF7368B80D Q36043444-977287FA-191A-4805-8D85-A1BA55901B15 Q36607383-85067D75-3F14-4C36-87B7-B854155DE704 Q37123147-6C6CB43E-0AD3-45C3-846E-C6E8FFFF2D80 Q37236968-BEAE2642-753D-463B-A843-D7082CA2DA2B Q37254256-FFC64BD5-A9CA-4387-826F-2401769A6707 Q37434776-46343495-F9FB-4F6D-9B3C-4BB9BA9491A3 Q37666763-553A95B4-8335-4D1B-84C9-4822652B11EA Q38074266-C844FC7C-5CF9-4BEB-BB7D-3BFBFA87368D Q38269151-0B6D54FD-CBFD-47B2-9379-4E341CFCFD3E Q38586294-83A1A49C-5849-47A4-A313-A57650BB14F0 Q38866173-449C0E15-FFBB-4178-B283-90296578C9EF Q40324111-C3747EDE-72FC-4E16-AF4A-251BD403C359 Q43047253-742601A1-FABF-4E7C-A9CC-FFF33D145813 Q51860606-28CC8079-CAE4-4C1D-A702-FECA0B9D25F9 Q52880885-82BFD255-1706-4093-BBDB-AEC6A8A6165F

P2860

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults

http://www.wikidata.org/entity/Q34154300

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@ast

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@en

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@nl

type

label

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@ast

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@en

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@nl

prefLabel

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@ast

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@en

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@nl

P1433

Q34154300-41814CAE-24A7-406D-BAE8-C500EAB3A24A

P1476

Q34154300-9D2B10C5-7E28-40EF-87A0-8E9E7826154B

P2093

Q34154300-1B95733C-2903-464E-9E51-AC16FC4931C1

Q34154300-7ABE11F2-9C26-4A6B-A892-D207CD951C75

Q34154300-B40ECD7D-8740-4B40-AF2A-0AD1F9AF75FD

Q34154300-C61FD321-F772-41B4-B902-A9252D8C4E37

P2860

Q34154300-02F33DAE-7F31-460C-839F-5D1B45630167

Q34154300-07DE0C22-2476-4071-A3CA-3A769ABD0122

Q34154300-0C338B15-6A73-4AAE-953E-332C7D1D4909

Q34154300-1F5C2180-77C4-41F9-9EA9-0B9D1E63684A

Q34154300-297F1B93-1895-4239-A646-FE1266E63366

Q34154300-29C59433-197A-424B-8099-7DC0C5E529A6

Q34154300-410F77D3-4035-4EBE-8A79-93EC2D7F12DC

Q34154300-45AD4E52-EDB7-4D89-A69D-95DBABEB10FF

Q34154300-4A6D2D2F-CBCD-4D0E-BFF0-90C8446EC776

Q34154300-504A6E51-5FD9-40E8-AA93-9F26B5D0FF97

P304

Q34154300-B1AC6692-E4F5-488E-8026-FA6F8586548D

P31

Q34154300-D8790577-7F3C-4C10-BC53-7E6C2C46E768

P356

Q34154300-4F264A74-06D0-43E3-8A49-0F467E28FC61

P407

Q34154300-10DECA2B-3AA8-4519-87A8-BD56CD62455C

P433

Q34154300-A80DAD40-CF6A-4B0D-B55A-B617E3DB1AA0

P478

Q34154300-E0FEFCE6-591E-4E72-8EA6-B1C20BFB0510

P50

Q34154300-1EC04BF3-D811-45AB-A0D9-22DE49C10852

P577

Q34154300-A05860A8-8393-48B4-8ABC-80E591B1032B

P5875

Q34154300-EBC69DBD-4819-463C-9BAA-8B61FA90A2F3

P698

Q34154300-0B68EEBD-F405-4A3C-A1F3-071D19D054D6

P921

Q34154300-1537423F-6F5C-494A-A75F-6D040BC79E32

Q34154300-3CE26245-6695-4A44-B6CE-269B8A5E0756

Q34154300-62A7662A-7EAF-4910-A79E-A88F27E69704

P932

Q34154300-86082DB0-4C3B-4222-A0FD-04F3740A8F62

P356

P1433

The Journal of Infectious Diseases

P1476

Phase II, randomized, double-b ...... irus vaccine in healthy adults

@en

P2093

Anne M Gregg

http://www.w3.org/2001/XMLSchema#string

Joan Bevilacqua

http://www.w3.org/2001/XMLSchema#string

Mike Watson

http://www.w3.org/2001/XMLSchema#string

Rex Biedenbender

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology and transmission dynamics of West Nile virus disease

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

A live, attenuated recombinant West Nile virus vaccine.

Pathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion

Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine

Preparation and immunogenic properties of a recombinant West Nile subunit vaccine

Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model

P304

75-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIQ003

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

Gustavo H Dayan

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49674368

http://www.w3.org/2001/XMLSchema#string

P698

21148499

http://www.w3.org/2001/XMLSchema#string

P921

West Nile virus

multicenter trial

P932

3086439

http://www.w3.org/2001/XMLSchema#string